Review Article | Published:

An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas


Our understanding of serrated colorectal polyps has increased dramatically over the past two decades and has led to a modern classification scheme for these lesions. Sessile serrated polyps with dysplasia represent the most clinically significant serrated polyp; however, the morphologic heterogeneity of dysplasia in sessile serrated polyps has only recently been recognized and correlated with MLH1 immunohistochemistry. Detailed morphologic analysis of traditional serrated adenomas has led to the recognition of flat and early forms of this polyp. Robust data on the risk of metachronous lesions in patients with serrated polyps are also beginning to emerge. This review will summarize our current understanding of serrated polyps and associated carcinomas with a focus on diagnostic criteria, morphologic heterogeneity, molecular findings, and natural history. Controversial issues in the diagnosis and classification of these polyps are also discussed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Munzy D, Bainbridge M, Chang K, Dinh H, Drummond J, Fowler G, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337.

  2. 2.

    Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148:77–87.

  3. 3.

    Torlakovic E, Snover DC. Serrated adenomatous polyposis in humans. Gastroenterology. 1996;110:748–755.

  4. 4.

    Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol. 2003;27:65–81.

  5. 5.

    Bateman AC, Shepherd NA. UK guidance for the pathological reporting of serrated lesions of the colorectum. J Clin Pathol. 2015;68:585–591.

  6. 6.

    East JE, Atkin WS, Bateman AC, Clark SK, Dolwani S, Ket SN, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017;66:1181–1196.

  7. 7.

    Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol. 1990;14:524–537.

  8. 8.

    Kudo S, Tamura S, Nakajima T, Yamano H, Kusaka H, Watanabe H. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc. 1996;44:8–14.

  9. 9.

    Bettington M, Walker N, Rosty C, Brown I, Clouston A, Wockner L, et al. Critical appraisal of the diagnosis of the sessile serrated adenoma. Am J Surg Pathol. 2014;38:158–166.

  10. 10.

    Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012;107:1315–1329.

  11. 11.

    O’Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006;30:1491–1501.

  12. 12.

    Sethi A, Hanson JA. A morphologic reappraisal of endoscopically but not histologically apparent polyps and the emergence of the overlooked goblet cell–rich hyperplastic polyp. Hum Pathol. 2015;46:1147–1152.

  13. 13.

    Hazewinkel Y, López-Cerón M, East JE, Rastogi A, Pellisé M, Nakajima T, et al. Endoscopic features of sessile serrated adenomas: validation by international experts using high-resolution white-light endoscopy and narrow-band imaging. Gastrointest Endosc. 2013;77:916–924.

  14. 14.

    IJspeert JEG, Bastiaansen BAJ, van Leerdam ME, Meijer GA, van Eeden S, Sanduleanu S, et al. Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps. Gut. 2016;65:963–970.

  15. 15.

    Tadepalli US, Feihel D, Miller KM, Itzkowitz SH, Freedman JS, Kornacki S, et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest Endosc. 2011;74:1360–1368.

  16. 16.

    Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3–43.

  17. 17.

    Hewett DG, Kaltenbach T, Sano Y, Tanaka S, Saunders BP, Ponchon T, et al. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology. 2012;143:599–607.

  18. 18.

    Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10.

  19. 19.

    Pai RK, Mojtahed A, Rouse RV, Soetikno RM, Kaltenbach T, Ma L, et al. Histologic and molecular analyses of colonic perineurial-like proliferations in serrated polyps: perineurial-like stromal proliferations are seen in sessile serrated adenomas. Am J Surg Pathol. 2011;35:1373–1380.

  20. 20.

    Erlenbach-Wünsch K, Bihl M, Hartmann A, Groisman GM, Vieth M, Agaimy A. Serrated epithelial colorectal polyps (hyperplastic polyps, sessile serrated adenomas) with perineurial stroma: Clinicopathological and molecular analysis of a new series. Ann Diagn Pathol. 2018;35:48–52.

  21. 21.

    Agaimy A, Stoehr R, Vieth M, Hartmann A. Benign serrated colorectal fibroblastic polyps/intramucosal Perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations. Am J Surg Pathol. 2010;34:1663–1671.

  22. 22.

    Torlakovic EE, Gomez JD, Driman DK, Parfitt JR, Wang C, Benerjee T, et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol. 2008;32:21–29.

  23. 23.

    Bartman AE, Sanderson SJ, Ewing SL, Niehans GA, Wiehr CL, Evans MK, et al. Aberrant expression of MUC5AC and MUC6 gastric mucin genes in colorectal polyps. Int J Cancer. 1999;80:210–218.

  24. 24.

    Bartley AN, Thompson PA, Buckmeier JA, Kepler CY, Hsu C-H, Snyder MS, et al. Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. Mod Pathol. 2009;23:169–176.

  25. 25.

    Gonzalo DH, Lai KK, Shadrach B, Goldblum JR, Bennett AE, Downs-Kelly E, et al. Gene expression profiling of serrated polyps identifies Annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol. 2013;230:420–429.

  26. 26.

    Kim JH, Rhee Y-Y, Kim K-J, Cho N-Y, Lee HS, Kang GH. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability. APMIS. 2014;122:1187–1195.

  27. 27.

    Bettington M, Walker N, Rosty C, Brown I, Clouston A, McKeone D, et al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut. 2017;66:97–106.

  28. 28.

    Liu C, Walker NI, Leggett BA, Whitehall VL, Bettington ML, Rosty C. Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry. Mod Pathol. 2017;30:1728–1738.

  29. 29.

    Yang JF, Tang S-J, Lash RH, Wu R, Yang Q. Anatomic distribution of sessile serrated adenoma/polyp with and without cytologic dysplasia. Arch Pathol Lab Med. 2015;139:388–393.

  30. 30.

    Sheridan TB, Fenton H, Lewin MR, Burkart AL, Iacobuzio-Donahue CA, Frankel WL, et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions “caught in the act.” Am J Clin Pathol. 2006;126:564–571.

  31. 31.

    Goldstein NS. Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol. 2006;125:132–145.

  32. 32.

    Burgess NG, Pellise M, Nanda KS, Hourigan LF, Zanati SA, Brown GJ, et al. Clinical and endoscopic predictors of cytological dysplasia or cancer in a prospective multicentre study of large sessile serrated adenomas/polyps. Gut. 2016;65:437–446.

  33. 33.

    Cenaj O, Gibson J, Odze RD. Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia. Mod Pathol. 2018;31:633–642.

  34. 34.

    Snover DC, Ahnen DJ, Burt RW, Odze RD. Serrated polyps of the colon and rectum and serrated polyposis. In: WHO Classification of tumors of the digestive system, 4th edition. Bosman FT, Carneiro F, Hruban RH, Theise ND, (Eds.). Lyon: International Agency for Research on Cancer, 2010. p. 160–165.

  35. 35.

    Bettington M, Liu C, Gill A, Walker N, Leggett B, Whitehall V, et al. BRAF V600E immunohistochemistry demonstrates that some sessile serrated lesions with adenomatous dysplasia may represent collision lesions. Histopathology 2019.

  36. 36.

    Bettington ML, Chetty R. Traditional serrated adenoma: an update. Hum Pathol. 2015;46:933–938.

  37. 37.

    Bettington ML, Walker NI, Rosty C, Brown IS, Clouston AD, McKeone DM, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015;28:414–427.

  38. 38.

    Wiland HO, Shadrach B, Allende D, Carver P, Goldblum JR, Liu X, et al. Morphologic and molecular characterization of traditional serrated adenomas of the distal colon and rectum. Am J Surg Pathol. 2014;38:1290–1297.

  39. 39.

    Kim K-M, Lee EJ, Kim Y-H, Chang DK, Odze RD. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype. Am J Surg Pathol. 2010;34:667–675.

  40. 40.

    Kim M-J, Lee E-J, Suh J-P, Chun S-M, Jang S-J, Kim DS, et al. Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions. Am J Clin Pathol. 2013;140:898–911.

  41. 41.

    Fu B, Yachida S, Morgan R, Zhong Y, Montgomery EA, Iacobuzio-Donahue CA. Clinicopathologic and genetic characterization of traditional serrated adenomas of the colon. Am J Clin Pathol. 2012;138:356–366.

  42. 42.

    Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of serrated polyps of colorectum. Histopathology. 2005;47:32–40.

  43. 43.

    Tsai J-H, Liau J-Y, Lin Y-L, Lin L-I, Cheng Y-C, Cheng M-L, et al. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod Pathol. 2014;27:1375–1385.

  44. 44.

    N Kalimuthu S, Serra S, Hafezi-Bakhtiari S, Colling R, Wang LM, Chetty R. Mucin-rich variant of traditional serrated adenoma: a distinct morphological variant. Histopathology. 2017;71:208–216.

  45. 45.

    Hiromoto T, Murakami T, Akazawa Y, Sasahara N, Saito T, Sakamoto N, et al. Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma. Histopathology. 2018;73:444–453.

  46. 46.

    Bettington M, Walker N, Rosty C, Brown I, Clouston A, McKeone D, et al. Serrated tubulovillous adenoma of the large intestine. Histopathology. 2016;68:578–587.

  47. 47.

    Hafezi-Bakhtiari S, Wang LM, Colling R, Serra S, Chetty R. Histological overlap between colorectal villous/tubulovillous and traditional serrated adenomas. Histopathology. 2015;66:308–313.

  48. 48.

    Chetty R, Hafezi-Bakhtiari S, Serra S, Colling R, Wang LM. Traditional serrated adenomas (TSAs) admixed with other serrated (so-called precursor) polyps and conventional adenomas: a frequent occurrence. J Clin Pathol. 2015;68:270–273.

  49. 49.

    Goldman H, Ming S, Hickock DF. Nature and significance of hyperplastic polyps of the human colon. Arch Pathol. 1970;89:349–354.

  50. 50.

    Bettington M, Rosty C, Whitehall V, Leggett B, McKeone D, Pearson S-A, et al. A morphological and molecular study of proposed early forms of traditional serrated adenoma. Histopathology. 2018;73:1023–1029.

  51. 51.

    Farris AB, Misdraji J, Srivastava A, Muzikansky A, Deshpande V, Lauwers GY, et al. Sessile serrated adenoma: challenging discrimination from other serrated colonic polyps. Am J Surg Pathol. 2008;32:30–35.

  52. 52.

    Chetty R, Bateman AC, Torlakovic E, Wang LM, Gill P, Al-Badri A, et al. A pathologist’s survey on the reporting of sessile serrated adenomas/polyps. J Clin Pathol. 2014;67:426–430.

  53. 53.

    Payne SR, Church TR, Wandell M, Rösch T, Osborn N, Snover D, et al. Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. Clin Gastroenterol Hepatol. 2014;12:1119–1126.

  54. 54.

    Erichsen R, Baron JA, Hamilton-Dutoit SJ, Snover DC, Torlakovic EE, Pedersen L, et al. Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps. Gastroenterology. 2016;150:895–902.

  55. 55.

    Huang CC, Frankel WL, Doukides T, Zhou X-P, Zhao W, Yearsley MM. Prolapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum. Hum Pathol. 2013;44:480–486.

  56. 56.

    Pai RK, Hart J, Noffsinger AE. Sessile serrated adenomas strongly predispose to synchronous serrated polyps in non-syndromic patients. Histopathology. 2010;56:581–588.

  57. 57.

    Yokoo H, Usman I, Wheaton S, Kampmeier PA. Colorectal polyps with extensive absorptive enterocyte differentiation: histologically distinct variant of hyperplastic polyps. Arch Pathol Lab Med. 1999;123:404–410.

  58. 58.

    García-Solano J, Pérez-Guillermo M, Conesa-Zamora P, Acosta-Ortega J, Trujillo-Santos J, Cerezuela-Fuentes P, et al. Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Hum Pathol. 2010;41:1359–1368.

  59. 59.

    Fernando WC, Miranda MS, Worthley DL, Togashi K, Watters DJ, Leggett BA, et al. The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort. Gastroenterol Res Pract. 2014;2014:374926.

  60. 60.

    Liu C, Bettington ML, Walker NI, Dwine J, Hartel GF, Leggett BA, et al. CpG Island Methylation in Sessile Serrated Adenomas Increases With Age, Indicating Lower Risk of Malignancy in Young Patients. Gastroenterology. 2018;155:1362–1365.

  61. 61.

    Cho H, Hashimoto T, Yoshida H, Taniguchi H, Ogawa R, Mori T, et al. Reappraisal of the genetic heterogeneity of sessile serrated adenoma/polyp. Histopathology. 2018;73:672–680.

  62. 62.

    Hashimoto T, Tanaka Y, Ogawa R, Mori T, Yoshida H, Taniguchi H, et al. Superficially serrated adenoma: a proposal for a novel subtype of colorectal serrated lesion. Mod Pathol. 2018;31:1588–1598.

  63. 63.

    Sekine S, Ogawa R, Hashimoto T, Motohiro K, Yoshida H, Taniguchi H, et al. Comprehensive characterization of RSPO fusions in colorectal traditional serrated adenomas. Histopathology. 2017;71:601–609.

  64. 64.

    Sekine S, Yamashita S, Tanabe T, Hashimoto T, Yoshida H, Taniguchi H, et al. Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. J Pathol. 2016;239:133–138.

  65. 65.

    Hashimoto T, Yamashita S, Yoshida H, Taniguchi H, Ushijima T, Yamada T, et al. WNT Pathway Gene Mutations Are Associated With the Presence of Dysplasia in Colorectal Sessile Serrated Adenoma/Polyps. Am J Surg Pathol. 2017;41:1188–1197.

  66. 66.

    Oh K, Redston M, Odze RD. Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. Hum Pathol. 2005;36:101–111.

  67. 67.

    Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol. 2011;24:1015–1022.

  68. 68.

    Bond CE, Umapathy A, Ramsnes I, Greco SA, Zhen Zhao Z, Mallitt K-A, et al. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int J Cancer. 2012;130:1567–1576.

  69. 69.

    Borowsky J, Dumenil T, Bettington M, Pearson S-A, Bond C, Fennell L, et al. The role of APC in WNT pathway activation in serrated neoplasia. Mod Pathol. 2018;31:495–504.

  70. 70.

    Murakami T, Mitomi H, Saito T, Takahashi M, Sakamoto N, Fukui N, et al. Distinct WNT/β-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. Mod Pathol. 2015;28:146–158.

  71. 71.

    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857.

  72. 72.

    Schreiner MA, Weiss DG, Lieberman DA. Proximal and large hyperplastic and nondysplastic serrated polyps detected by colonoscopy are associated with neoplasia. Gastroenterology. 2010;139:1497–1502.

  73. 73.

    Hazewinkel Y, de Wijkerslooth TR, Stoop EM, Bossuyt PM, Biermann K, van de Vijver MJ, et al. Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy. 2014;46:219–224.

  74. 74.

    Anderson JC, Lisovsky M, Greene MA, Hagen C, Srivastava A. Factors Associated With Classification of Hyperplastic Polyps as Sessile Serrated Adenomas/Polyps on Morphologic Review. J Clin Gastroenterol. 2017;52:524–529.

  75. 75.

    Holme Ø, Bretthauer M, Eide TJ, Løberg EM, Grzyb K, Løberg M, et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut. 2015;64:929–936.

  76. 76.

    Lu F-I, van Niekerk DW, Owen D, Tha SPL, Turbin DA, Webber DL. Longitudinal outcome study of sessile serrated adenomas of the colorectum: an increased risk for subsequent right-sided colorectal carcinoma. Am J Surg Pathol. 2010;34:927–934.

  77. 77.

    Sawhney MS, Farrar WD, Gudiseva S, Nelson DB, Lederle FA, Rector TS, et al. Microsatellite instability in interval colon cancers. Gastroenterology. 2006;131:1700–1705.

  78. 78.

    Soong TR, Nayor J, Stachler MD, Perencevich M, Jajoo K, Saltzman JR, et al. Clinicopathologic and genetic characteristics of interval colorectal carcinomas favor origin from missed or incompletely excised precursors. Mod Pathol 2018.

  79. 79.

    Pohl H, Srivastava A, Bensen SP, Anderson P, Rothstein RI, Gordon SR, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology. 2013;144:74–80.

  80. 80.

    van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol. 2006;101:343–350.

  81. 81.

    Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997;112:24–28.

  82. 82.

    Zhao S, Wang S, Pan P, Xia T, Chang X, Yang X, et al. Magnitude, Risk Factors, and Factors Associated With Adenoma Miss Rate of Tandem Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology. 2019.

  83. 83.

    Li D, Jin C, McCulloch C, Kakar S, Berger BM, Imperiale TF, et al. Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am J Gastroenterol. 2009;104:695–702.

  84. 84.

    Gao Q, Tsoi KKF, Hirai HW, Wong MCS, Chan FKL, Wu JCY, et al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:501–509.

  85. 85.

    Ng SC, Ching JYL, Chan VCW, Wong MCS, Tang R, Wong S, et al. Association between serrated polyps and the risk of synchronous advanced colorectal neoplasia in average-risk individuals. Aliment Pharmacol Ther. 2015;41:108–115.

  86. 86.

    Hiraoka S, Kato J, Fujiki S, Kaji E, Morikawa T, Murakami T, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology. 2010;139:1503–1510, 1510.

  87. 87.

    Egoavil C, Juárez M, Guarinos C, Rodríguez-Soler M, Hernández-Illán E, Alenda C, et al. Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology. 2017;153:106–112.

  88. 88.

    Macaron C, Vu HT, Lopez R, Pai RK, Burke CA. Risk of Metachronous Polyps in Individuals With Serrated Polyps. Dis Colon Rectum. 2015;58:762–768.

  89. 89.

    Anderson JC, Butterly LF, Robinson CM, Weiss JE, Amos C, Srivastava A. Risk of Metachronous High- Risk Adenomas and Large Serrated Polyps in Individuals With Serrated Polyps on Index Colonoscopy: Data From the New Hampshire Colonoscopy Registry. Gastroenterology. 2018;154:117–127.

  90. 90.

    Bensen SP, Cole BF, Mott LA, Baron JA, Sandler RS, Haile R. Colorectal hyperplastic polyps and risk of recurrence of adenomas and hyperplastic polyps. Polyps Prevention Study. Lancet. 1999;354:1873–1874.

  91. 91.

    Lazarus R, Junttila OE, Karttunen TJ, Mäkinen MJ. The risk of metachronous neoplasia in patients with serrated adenoma. Am J Clin Pathol. 2005;123:349–359.

  92. 92.

    Laiyemo AO, Murphy G, Sansbury LB, Wang Z, Albert PS, Marcus PM, et al. Hyperplastic polyps and the risk of adenoma recurrence in the polyp prevention trial. Clin Gastroenterol Hepatol. 2009;7:192–197.

  93. 93.

    Pereyra L, Zamora R, Gómez EJ, Fischer C, Panigadi GN, González R, et al. Risk of Metachronous Advanced Neoplastic Lesions in Patients with Sporadic Sessile Serrated Adenomas Undergoing Colonoscopic Surveillance. Am J Gastroenterol. 2016;111:871–878.

  94. 94.

    Rosty C, Buchanan DD, Walsh MD, Pearson S-A, Pavluk E, Walters RJ, et al. Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am J Surg Pathol. 2012;36:876–882.

  95. 95.

    IJspeert JEG, Rana SaQ, Atkinson NSS, van Herwaarden YJ, Bastiaansen BaJ, van Leerdam ME, et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut. 2017;66:278–284.

  96. 96.

    Carballal S, Rodríguez-Alcalde D, Moreira L, Hernández L, Rodríguez L, Rodríguez-Moranta F, et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut. 2016;65:1829–1837.

  97. 97.

    Melson J, Ma K, Arshad S, Greenspan M, Kaminsky T, Melvani V, et al. Presence of small sessile serrated polyps increases rate of advanced neoplasia upon surveillance compared with isolated low-risk tubular adenomas. Gastrointest Endosc. 2016;84:307–314.

  98. 98.

    Glazer E, Golla V, Forman R, Zhu H, Levi G, Bodenheimer HC. Serrated adenoma is a risk factor for subsequent adenomatous polyps. Dig Dis Sci. 2008;53:2204–2207.

  99. 99.

    Yoon JY, Kim HT, Hong SP, Kim HG, Kim J-O, Yang D-H, et al. High-risk metachronous polyps are more frequent in patients with traditional serrated adenomas than in patients with conventional adenomas: a multicenter prospective study. Gastrointest Endosc. 2015;82:1087–1093.

  100. 100.

    Edelstein DL, Axilbund JE, Hylind LM, Romans K, Griffin CA, Cruz-Correa M, et al. Serrated polyposis: rapid and relentless development of colorectal neoplasia. Gut. 2013;62:404–408.

  101. 101.

    Gala MK, Mizukami Y, Le LP, Moriichi K, Austin T, Yamamoto M, et al. Germline mutations in oncogeneinduced senescence pathways are associated with multiple sessile serrated adenomas. Gastroenterology. 2014;146:520–529.

  102. 102.

    Buchanan DD, Clendenning M, Zhuoer L, Stewart JR, Joseland S, Woodall S, et al. Lack of evidence for germline RNF43 mutations in patients with serrated polyposis syndrome from a large multinational study. Gut. 2017;66:1170–1172.

  103. 103.

    Quintana I, Mejías-Luque R, Terradas M, Navarro M, Piñol V, Mur P, et al. Evidence suggests that germline RNF43 mutations are a rare cause of serrated polyposis. Gut. 2018;67:2230–2232.

  104. 104.

    Yan HHN, Lai JCW, Ho SL, Leung WK, Law WL, Lee JFY, et al. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation. Gut. 2017;66:1645–1656.

  105. 105.

    Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol. 2012;107:770–778.

  106. 106.

    Rosty C, Brosens LA, Dekker E, Nagtegaal ID. Serrated polyposis. In: WHO Classification of Tumours of the Digestive System, 5th Edition. Lyon: International Agency for Research on Cancer, 2019. Forthcoming.

  107. 107.

    Rosty C, Walsh MD, Walters RJ, Clendenning M, Pearson S-A, Jenkins MA, et al. Multiplicity and Molecular Heterogeneity of Colorectal Carcinomas in Individuals With Serrated Polyposis. Am J Surg Pathol. 2013;37:434–442.

  108. 108.

    Vemulapalli KC, Rex DK. Failure to recognize serrated polyposis syndrome in a cohort with large sessile colorectal polyps. Gastrointest Endosc. 2012;75:1206–1210.

  109. 109.

    Crowder CD, Sweet K, Lehman A, Frankel WL. Serrated Polyposis Is an Underdiagnosed and Unclear Syndrome: The Surgical Pathologist has a Role in Improving Detection. Am J Surg Pathol. 2012;36:1178–1185.

  110. 110.

    Parry S, Burt RW, Win AK, Aung YK, Woodall S, Arnold J, et al. Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. N Z Med J. 2017;130:57–67.

  111. 111.

    Boparai KS, Reitsma JB, Lemmens V, van Os T a. M, Mathus-Vliegen EMH, Koornstra JJ, et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut. 2010;59:1222–1225.

  112. 112.

    Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62:367–386.

  113. 113.

    Tuppurainen K, Mäkinen JM, Junttila O, Liakka A, Kyllönen AP, Tuominen H, et al. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol. 2005;207:285–294.

  114. 114.

    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2015;148:88–99.

  115. 115.

    Patil DT, Shadrach BL, Rybicki LA, Leach BH, Pai RK. Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status. Mod Pathol. 2012;25:1423–1431.

  116. 116.

    Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063–6069.

  117. 117.

    Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, et al. BRAF-mutated, Microsatellitestable Adenocarcinoma of the Proximal Colon: An Aggressive Adenocarcinoma With Poor Survival, Mucinous Differentiation, and Adverse Morphologic Features. Am J Surg Pathol. 2012;36:744–752.

  118. 118.

    Landau MS, Kuan S-F, Chiosea S, Pai RK. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. Hum Pathol. 2014;45:1704–1712.

  119. 119.

    Rosty C, Williamson EJ, Clendenning M, Walters RJ, Walsh MD, Win AK, et al. Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 2014;106.

  120. 120.

    Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006;8:582–588.

  121. 121.

    Hinoue T, Weisenberger DJ, Lange CPE, Shen H, Byun H-M, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271–282.

  122. 122.

    Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007;56:1564–1571.

  123. 123.

    Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90–96.

  124. 124.

    Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129:837–845.

  125. 125.

    Farchoukh L, Kuan S-F, Dudley B, Brand R, Nikiforova M, Pai RK. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas. Am J Surg Pathol. 2016;40:1390–1399.

Download references

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Rish K. Pai or Christophe Rosty.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11